Biodesix (BDSX) Liabilities and Shareholders Equity (2019 - 2026)

Biodesix (BDSX) has reported Liabilities and Shareholders Equity for 8 consecutive years, with $94.6 million the latest figure, recorded in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $94.6 million, up 9.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $358.6 million (down 10.82% YoY), and the FY2025 annual result was $87.5 million, down 10.04% from the prior year.
• Liabilities and Shareholders Equity was $94.6 million for Q1 2026 at Biodesix, up from $87.5 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $115.8 million in Q2 2024 and troughed at $61.7 million in Q1 2022.
• Average Liabilities and Shareholders Equity over 5 years is $87.4 million, with a median of $87.5 million recorded in 2025.
• Year-over-year, Liabilities and Shareholders Equity slumped 46.62% in 2022 and jumped 49.24% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $92.9 million in 2022, then climbed by 6.66% to $99.1 million in 2023, then fell by 1.87% to $97.2 million in 2024, then dropped by 10.04% to $87.5 million in 2025, then rose by 8.19% to $94.6 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $94.6 million in Q1 2026, $87.5 million in Q4 2025, and $88.7 million in Q3 2025.